Apogee Therapeutics (APGE) Operating Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Operating Expenses data on file, last reported at $82.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $82.8 million, up 31.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $305.3 million (up 26.26% YoY), and the FY2025 annual result was $285.6 million, up 31.69% from the prior year.
• Operating Expenses advanced to $82.8 million in Q1 2026 per APGE's latest filing, from $78.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $82.8 million in Q1 2026 and troughed at $1.8 million in Q2 2022.
• A 5-year average of $44.0 million and a median of $41.2 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 939.92% in 2023, then rose 2.87% in 2025.
• A 5-year view of Operating Expenses shows it stood at $14.1 million in 2022, then surged by 163.53% to $37.2 million in 2023, then jumped by 104.23% to $75.9 million in 2024, then advanced by 2.87% to $78.1 million in 2025, then gained by 6.04% to $82.8 million in 2026.
• Business Quant data shows APGE's Operating Expenses at $82.8 million in Q1 2026, $78.1 million in Q4 2025, and $71.3 million in Q3 2025.